People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...

A so-called "natural Mounjaro" drink has gone viral online thanks to claims it can lead to significant weight loss. Here's ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...